FOR IMMEDIATE RELEASE

Regen Health Care Group Partners with Boustead APEX, Boustead & Co, and Raffles Capital US to Pursue U.S. Listing, Driving Global Expansion of Stem Cell Regeneration Therapies

Shenzhen, China – 9 Aug 2025 – Regen Health Care Group, a leading provider of advanced stem cell regeneration therapies, announced today its strategic partnership with Boustead APEX, Inc., Boustead & Co, and cornerstone investor Raffles Capital US to bring the company public in the United States. This milestone marks not only a critical breakthrough in Regen’s global expansion strategy but also underscores the rising prominence of Asia’s cutting-edge regenerative medicine sector on the international stage.

Over the past decade, the global regenerative medicine industry has rapidly transitioned from laboratory research to clinical application, with stem cell therapies emerging as one of its most disruptive innovations. Leveraging years of expertise in stem cell research, clinical validation, and large-scale application, Regen has built a strong medical network and brand reputation across Asia. The planned U.S. listing will provide substantial capital infusion, an international governance framework, and trust from leading global investors.

As the world faces accelerating population aging and rising prevalence of chronic and degenerative diseases, the demand for advanced regenerative therapies is growing exponentially. Partnering with Boustead APEX, Boustead & Co, and Raffles Capital US, Regen aims to leverage a U.S. public listing to strengthen its R&D capabilities, expand its range of clinical indications, and deepen collaboration with top-tier international research institutions and healthcare networks, ensuring that its innovations reach patients faster.

Keith Moore, Executive Chairman of Boustead & Co, stated:

"Regen Health Care Group represents the type of high-growth, transformative company we are proud to support in the U.S. capital markets. The demand for advanced regenerative medicine is growing exponentially, and a U.S. listing will give Regen the platform and resources needed to lead this industry globally."

Dr. Marcuz Tan, CEO of Boustead APEX, Inc., commented:

"Our role is to empower visionary companies like Regen to reach the world stage without compromising on their mission or control. By leveraging our listing expertise and U.S. capital market network, we are confident that Regen will achieve a valuation that reflects its true market potential and scientific excellence."

Dr. Charlie In, Founder of Raffles Capital US, said:

"As the cornerstone investor in this partnership, we firmly believe in Regen’s technical capabilities and market potential in regenerative medicine. With the support of the U.S. capital markets, Regen will be able to accelerate the commercialization of its technology and expand its international footprint, bringing life-changing treatments to patients worldwide."

Li Jing, CEO of Regen Health Care Group, added:

"For years, our team has been dedicated to advancing cell regeneration therapy to improve lives. Partnering with Boustead APEX, Boustead & Co, and Raffles Capital US gives us the ideal platform to share our breakthroughs with the world and deliver hope to more patients globally."

This partnership highlights the deepening synergy between Asia’s healthcare innovators and the liquidity, investor base, and prestige of the U.S. capital markets. The transaction is expected to begin with an OTCQB listing, with a planned uplisting to NASDAQ or NYSE within 12–18 months.

Forward-Looking Statements

This release contains forward-looking statements, including potential benefits of supply chain finance, possible valuation outcomes, and indicative timelines for U.S. listings. These statements are based on management’s current expectations and involve risks and uncertainties that could cause actual results to differ materially. No assurance can be given that any particular result will be achieved. Factors that could affect outcomes include market conditions, regulatory approvals, the company’s financial performance, and other risks described in company disclosures. Readers should not place undue reliance on forward-looking statements and should consult qualified professional advisors. 

About Boustead APEX, Inc.

Boustead APEX, Inc. “BAI” provides corporate advisory services including but not limited to private-to-public listing strategy, mergers and acquisition deal structuring consultation, up-valuation and up-listing of undervalued companies.

About Boustead & Company Limited

Boustead & Company Limited is a diversified financial services firm headquartered in Irvine, CA with offices in Austin, Boca Raton, San Francisco, New York, Beijing, London, Mauritius, Monaco, Singapore, and Zug. Boustead & Company Limited and its affiliates offer mergers & acquisitions, capital markets, project finance, pre-transaction advisory, financial restructuring, sales & trading, crowdfunding, and business valuation services to emerging growth and middle-market companies. 

About Raffles Capital US

Raffles Capital US acts as venture-accelerator for promising firms that are ready and qualifies for a public listing on a North-America bourse within 18-24 months of vesting. RC works with companies that can deliver social impact bringing prosperity and progress to the people and planet. These firms’ purpose must be in alignment with the UN 17 Sustainable Development Goals.

About Regen Health Care Group

Regen Health Care Group is a leading provider of stem cell regeneration therapy, offering scientifically validated treatments designed to restore and repair damaged tissues and improve quality of life. Based in Shenzhen, China, Regen serves patients across Asia and is committed to advancing research in regenerative medicine.

Media Report: 丽晶医疗集团携手宝德亚太、宝德投行及莱福士资本 推动赴美上市，加速干细胞再生疗法全球化进程

1、中金在线：http://news.cnfol.com/shangyeyaowen/20250822/31569066.shtml

2、凤凰财经：https://finance.ifeng.com/c/8m1g9arhBX1

3、和讯新闻：http://news.hexun.com/2025-08-22/221052636.html

4、财经网：http://industry.caijing.com.cn/20250822/5108760.shtml

5、界面新闻：https://www.jiemian.com/article/13223059.html

6、证券之星：https://finance.stockstar.com/IG2025082200022384.shtml

7、中国财富网https://www.cfbond.com/2025/08/22/991100064.html